[go: up one dir, main page]

AU3817899A - Therapy of atherosclerosis - Google Patents

Therapy of atherosclerosis

Info

Publication number
AU3817899A
AU3817899A AU38178/99A AU3817899A AU3817899A AU 3817899 A AU3817899 A AU 3817899A AU 38178/99 A AU38178/99 A AU 38178/99A AU 3817899 A AU3817899 A AU 3817899A AU 3817899 A AU3817899 A AU 3817899A
Authority
AU
Australia
Prior art keywords
atherosclerosis
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38178/99A
Inventor
Isabelle Ginon
John Mcgregor
Robin Poston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Kings College London
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Kings College London filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU3817899A publication Critical patent/AU3817899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU38178/99A 1998-04-15 1999-04-15 Therapy of atherosclerosis Abandoned AU3817899A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98420066 1998-04-15
EP98420066 1998-04-15
PCT/EP1999/002577 WO1999052551A1 (en) 1998-04-15 1999-04-15 Therapy of atherosclerosis

Publications (1)

Publication Number Publication Date
AU3817899A true AU3817899A (en) 1999-11-01

Family

ID=8235626

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38178/99A Abandoned AU3817899A (en) 1998-04-15 1999-04-15 Therapy of atherosclerosis

Country Status (2)

Country Link
AU (1) AU3817899A (en)
WO (1) WO1999052551A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952960A1 (en) 1999-11-03 2001-05-10 Mark Andre Freyberg Method for identifying anti-apoptotic compounds
CU23736A1 (en) 2009-05-04 2011-11-15 Centro Inmunologia Molecular ANTIBODIES RECOGNIZING SULFATIDES AND SULFATED PROTEOGLYCANS AND THEIR USE
EP4210750A4 (en) * 2020-09-10 2024-09-25 Implicit Bioscience Limited METHODS AND THERAPEUTIC AGENTS FOR THE TREATMENT OF MYOCARDIAL INFARCTION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312315D0 (en) * 1993-06-15 1993-07-28 Poston Robin Leukocyte adhesion assay
WO1996009388A1 (en) * 1994-09-19 1996-03-28 The Regents Of The University Of California Novel anti-vh3-15 reagents, vh3-15 polypeptides, cell surface antigens, and methods for their detection and use
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
AU724191B2 (en) * 1996-08-29 2000-09-14 Merck & Co., Inc. Integrin antagonists

Also Published As

Publication number Publication date
WO1999052551A1 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
AU3300599A (en) Per-method designation of security requirements
AU9790198A (en) Compounds and methods
AU1430699A (en) Production of propylene
AU6883798A (en) Method of anesthesia
AU3867400A (en) Methods of using bioelastomers
AU3514299A (en) Method of providing secure user access
AU2882299A (en) Anti-asthma therapy
AU5562999A (en) Methods of modulating of angiogenesis
AU7474998A (en) Haloisoquinoline carboxamide
AU1541499A (en) Human phosphatases
AU3969099A (en) Controlled activation of targeted radionuclides
AU1933297A (en) Manufacture of elongate members
AU7421598A (en) Methods of enhancing functioning of the large intestine
AU3817899A (en) Therapy of atherosclerosis
AU1208799A (en) Recovery of gamma-pyrones
AU8102498A (en) Preparation of diaryl-benzopyrans
AU9119998A (en) Method of time-to-talk calculation
AU6993598A (en) Manufacture of alpha-tocopherol
AU3061499A (en) Aryl- and heteroarylamides of carboalkoxysulfanilic acids
AU5670898A (en) Manufacture of elongate members
AU7545998A (en) Treatment of osteoporosis
AU3040797A (en) Preparation of alpha-fluoroketones
AU5753599A (en) Treatment of fibres
AU3705597A (en) Preparation of aminomethyl-phenylimidazoles
AU1273700A (en) Method of permanenting

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase